In lung cancer, a particular subset of CAF: CD200-positive CAF was uncovered to elevate the sensitivity of cancer cells to EGFR-tyrosine kinase inhibitor (EGFR-TKI), gefitinib, and the sensitizing potential was deprived when CD200 was knocked out [195]. This evidence concerns the gene EGFR and cancer.